Tandem Diabetes Care's ROE % for the quarter that ended in Mar. 2026 was -56.73%. Tandem Diabetes Care's PB Ratio for the quarter that ended in Mar. 2026 was 9.88.
Tandem Diabetes Care's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -5.74%.
Tandem Diabetes Care ROE % Adjusted to Book Value Related Terms
Tandem Diabetes Care ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care ROE % Adjusted to Book Value Chart
LTS:0M0F vs CNMD, AORT, LMRI: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -5.74% mean?
Tandem Diabetes Care (LTS:0M0F) has a ROE % Adjusted to Book Value of -5.74% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's ROE % Adjusted to Book Value too high?
Tandem Diabetes Care's current ROE % Adjusted to Book Value is -5.74%. Overall, Tandem Diabetes Care has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's ROE % Adjusted to Book Value compare to CNMD and AORT?
Tandem Diabetes Care's ROE % Adjusted to Book Value of -5.74% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current ROE % Adjusted to Book Value is -5.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.77, compared to a current price of $15.63 — trading 47.5% below its estimated fair value. The current ROE % Adjusted to Book Value is -5.74%. Tandem Diabetes Care's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current ROE % Adjusted to Book Value is -5.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $15.63 is trading 47.5% below its estimated GF Value™ of $29.77.
GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.
Key valuation signals for LTS:0M0F:
ROE % Adjusted to Book Value: -5.74%
GF Value™: $29.77 vs. price of $15.63 (47.5% below fair value)
No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
69GF Score
Get the complete analysis for LTS:0M0F
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M0F has been successfully added to your 
